

Andrew J Davies

List of Publications by Citations

Source: <https://exaly.com/author-pdf/5992857/andrew-j-davies-publications-by-citations.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

50
papers

2,718
citations

21
h-index

52
g-index

55
ext. papers

3,518
ext. citations

8.4
avg, IF

4.77
L-index

#	Paper	IF	Citations
50	PI3K inhibition by idelalisib in patients with relapsed indolent lymphoma. <i>New England Journal of Medicine</i> , 2014 , 370, 1008-18	59.2	784
49	Obinutuzumab for the First-Line Treatment of Follicular Lymphoma. <i>New England Journal of Medicine</i> , 2017 , 377, 1331-1344	59.2	365
48	Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. <i>Lancet, The</i> , 2018 , 391, 659-667	40	231
47	Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma. <i>Nature Genetics</i> , 2016 , 48, 183-836.3	36.3	116
46	Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study. <i>Journal of Clinical Oncology</i> , 2017 , 35, 544-551	2.2	99
45	Molecular High-Grade B-Cell Lymphoma: Defining a Poor-Risk Group That Requires Different Approaches to Therapy. <i>Journal of Clinical Oncology</i> , 2019 , 37, 202-212	2.2	99
44	A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. <i>Clinical Cancer Research</i> , 2017 , 23, 4127-4137	12.9	98
43	Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial. <i>Lancet Oncology, The</i> , 2019 , 20, 649-662	21.7	95
42	Antagonistic human FcγRIIB (CD32B) antibodies have anti-tumor activity and overcome resistance to antibody therapy in vivo. <i>Cancer Cell</i> , 2015 , 27, 473-88	24.3	84
41	Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study. <i>Lancet Oncology, The</i> , 2014 , 15, 343-52	21.7	82
40	Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial. <i>Lancet Haematology, the</i> , 2017 , 4, e272-e282	14.6	74
39	FDG-PET maximum standardised uptake value is associated with variation in survival: analysis of 498 lung cancer patients. <i>Lung Cancer</i> , 2007 , 55, 75-8	5.9	58
38	Guidelines for the diagnosis and management of primary central nervous system diffuse large B-cell lymphoma. <i>British Journal of Haematology</i> , 2019 , 184, 348-363	4.5	50
37	Role of Radiation Therapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018 , 100, 652-669	4	41
36	Subcutaneous Rituximab for the Treatment of B-Cell Hematologic Malignancies: A Review of the Scientific Rationale and Clinical Development. <i>Advances in Therapy</i> , 2017 , 34, 2210-2231	4.1	39
35	Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma. <i>Leukemia</i> , 2019 , 33, 2762-2766	10.7	39
34	Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas. <i>Blood</i> , 2018 , 131, 2120-2124	2.2	39

33	Obinutuzumab in hematologic malignancies: lessons learned to date. <i>Cancer Treatment Reviews</i> , 2015 , 41, 784-92	14.4	37
32	Antibody responses after SARS-CoV-2 vaccination in patients with lymphoma. <i>Lancet Haematology</i> , 2021 , 8, e542-e544	14.6	37
31	Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression. <i>Haematologica</i> , 2019 , 104, 1202-1208	6.6	33
30	Obinutuzumab-Based Induction and Maintenance Prolongs Progression-Free Survival (PFS) in Patients with Previously Untreated Follicular Lymphoma: Primary Results of the Randomized Phase 3 GALLIUM Study. <i>Blood</i> , 2016 , 128, 6-6	2.2	23
29	A Prospective Randomised Trial of Targeted Therapy for Diffuse Large B-Cell Lymphoma (DLBCL) Based upon Real-Time Gene Expression Profiling: The Remodl-B Study of the UK NCRI and SAKK Lymphoma Groups (ISRCTN51837425). <i>Blood</i> , 2015 , 126, 812-812	2.2	19
28	Double hit lymphoma: How do we define it and how do we treat it?. <i>Best Practice and Research in Clinical Haematology</i> , 2018 , 31, 233-240	4.2	16
27	Tailoring front-line therapy in diffuse large B-cell lymphoma: who should we treat differently?. <i>Hematology American Society of Hematology Education Program</i> , 2017 , 2017, 284-294	3.1	16
26	Idelalisib for relapsed/refractory indolent B-cell non-Hodgkin's lymphoma: an overview of pharmacokinetics and clinical trial outcomes. <i>Expert Review of Hematology</i> , 2015 , 8, 581-93	2.8	15
25	Current treatment of double hit and double expressor lymphoma. <i>Hematology American Society of Hematology Education Program</i> , 2017 , 2017, 295-297	3.1	14
24	A phase II study to assess the safety and efficacy of the dual mTORC1/2 inhibitor vistusertib in relapsed, refractory DLBCL. <i>Hematological Oncology</i> , 2019 , 37, 352-359	1.3	12
23	Double-hit lymphoma: So what?. <i>Hematological Oncology</i> , 2019 , 37 Suppl 1, 19-23	1.3	10
22	Evaluation of High-Throughput Genomic Assays for the Fc Gamma Receptor Locus. <i>PLoS ONE</i> , 2015 , 10, e0142379	3.7	10
21	High-dose chemotherapy and autologous stem cell transplantation in enteropathy-associated and other aggressive T-cell lymphomas: a UK NCRI/Cancer Research UK Phase II Study. <i>Bone Marrow Transplantation</i> , 2019 , 54, 465-468	4.4	8
20	Mature Response Data From a Phase 2 Study Of PI3K-Delta Inhibitor Idelalisib In Patients With Double (Rituximab and Alkylating Agent)-Refractory Indolent B-Cell Non-Hodgkin Lymphoma (iNHL). <i>Blood</i> , 2013 , 122, 85-85	2.2	7
19	The management of primary mediastinal B-cell lymphoma: a British Society for Haematology Good Practice Paper. <i>British Journal of Haematology</i> , 2019 , 185, 402-409	4.5	7
18	Post Relapse Survival Rates in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2016 , 128, 4204-4204	2.2	5
17	Health-related quality of life in the phase III GALLIUM study of obinutuzumab- or rituximab-based chemotherapy in patients with previously untreated advanced follicular lymphoma. <i>Annals of Hematology</i> , 2020 , 99, 2837-2846	3	5
16	Results of a UK National Cancer Research Institute Phase II study of brentuximab vedotin using a response-adapted design in the first-line treatment of patients with classical Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or comorbidity (BREVITY). <i>British Journal of Haematology</i> , 2021 , 188, 43-51	4.5	5

15	Immune responses against SARS-CoV-2 variants after two and three doses of vaccine in B-cell malignancies: UK PROSECO study.. <i>Nature Cancer</i> , 2022 ,	15.4	5
14	Subcutaneous rituximab with recombinant human hyaluronidase in the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia. <i>Future Oncology</i> , 2018 , 14, 1691-1699	3.6	3
13	Advances in the molecular diagnosis of diffuse large B-cell lymphoma in the era of precision medicine. <i>Expert Review of Molecular Diagnostics</i> , 2016 , 16, 1093-1102	3.8	3
12	Patient-reported outcomes data from a phase 2 study of idelalisib in patients with refractory indolent B-cell non-Hodgkin lymphoma (iNHL).. <i>Journal of Clinical Oncology</i> , 2014 , 32, e19554-e19554	2.2	3
11	Comparative analysis of gene expression platforms for cell-of-origin classification of diffuse large B-cell lymphoma shows high concordance. <i>British Journal of Haematology</i> , 2021 , 192, 599-604	4.5	3
10	Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Long-Term Efficacy and Safety Results from a Phase 2 Study. <i>Blood</i> , 2020 , 136, 38-39	2.2	2
9	ACCEPT - combining acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for Diffuse Large B-cell Lymphoma (DLBCL): study protocol for a Phase Ib/II open-label non-randomised clinical trial. <i>F1000Research</i> , 2020 , 9, 941	3.6	2
8	Tissue Microarray Is a Useful Tool in the Evaluation of Genes Implicated in Transformation of Follicular Lymphoma.. <i>Blood</i> , 2004 , 104, 2267-2267	2.2	1
7	Longer Term Efficacy and Safety of Subcutaneous Compared with Intravenous Rituximab: Updated Results of the Phase 3 SABRINA Study. <i>Blood</i> , 2016 , 128, 1103-1103	2.2	1
6	Oasis: An international phase I trial of obinutuzumab, venetoclax plus ibrutinib in relapsed/refractory mantle cell lymphoma.. <i>Journal of Clinical Oncology</i> , 2016 , 34, TPS7583-TPS7583	2.2	1
5	Risk-Stratified Sequential Treatment with Ibrutinib and Rituximab (IR) and IR-CHOP for De-Novo Post-Transplant Lymphoproliferative Disorder: Results of the Tidal Trial. <i>Blood</i> , 2021 , 138, 2492-2492	2.2	1
4	Multinational Association of Supportive Care in Cancer (MASCC) expert opinion/guidance on the use of clinically assisted nutrition in patients with advanced cancer. <i>Supportive Care in Cancer</i> , 2021 , 1	3.9	0
3	An Open-Label, Phase 1 Study of R-CVP in Combination with Inotuzumab Ozogamicin in Patients with CD22-Positive B-Cell Non-Hodgkin Lymphoma: Preliminary Safety and Efficacy Data. <i>Blood</i> , 2012 , 120, 1633-1633	2.2	
2	Whole Genome Sequencing in Sequential Biopsies Reveals the Genetic Evolution of Follicular Lymphoma to Transformed Follicular Lymphoma. <i>Blood</i> , 2012 , 120, 145-145	2.2	
1	DLBCL outcomes: much ventured, much GAINED. <i>Blood</i> , 2021 , 137, 2277-2278	2.2	